Greek study aims to better measure Hypoparathyroidism's impact
NCT ID NCT07160348
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will translate and test two questionnaires (HPES-Symptom and HPES-Impact) for Greek-speaking adults with chronic hypoparathyroidism. Researchers will enroll 200 patients across several hospitals in Greece. The goal is to ensure the questionnaires accurately capture patients' symptoms and daily-life challenges in Greek, so doctors can use them to improve care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could provide a reliable tool to measure how hypoparathyroidism affects patients in Greece, helping doctors better understand and manage the condition.
- What could go wrong
- This is a translation and validation study, not a treatment trial. It won't directly improve patient health, and the questionnaire may not capture all important aspects of the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a daily shot free teens from calcium pills?
- Weekly shot could free hypoparathyroidism patients from daily pills
- New daily shot could ease rare hormone disorder
- Glowing goggles could prevent calcium crash after thyroid surgery
- MRNA therapy offers hope for rare hormone disorder
- MRNA therapy takes on rare hormone disorder